1. Inhibition of ACL by ETC-1002.
Inhibition of ACL by ETC ACL catalyzes the conversion of citrate plus CoA to acetyl-CoA plus oxaloacetate. Acetyl-CoA is then converted in a series of steps to HMG-CoA, which is converted by HMG-CoA reductase into mevalonic acid. This is the rate-limiting step in the formation of cholesterol. Mevalonic acid is subsequently converted in a number of additional steps into cholesterol. ETC-1002 inhibits ACL, whereas statins inhibit HMG-CoA reductase. HMG, 3-hydroxy-3-methylglutaryl.
Philip J. Barter, and Kerry-Anne Rye Pharmacol Rev 2016;68:
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics